{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
52 FR 30054 cough/cold:antitussive horehound
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2019)
Source URL:
First approved in 2016
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2016)
Source URL:
First approved in 2016
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2021)
Source URL:
First approved in 2016
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M021
(2024)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE